The research analysts working at Truisti Securiti have already increased the EPS estimate for the shares of PFE in one of their research reports that were sent out to investors and clients. G. Gilbert, the analyst from the investment firm has now forecasted that the company dealing in pharmaceuticals would now post an EPS of $4.14 for this year. The brokerage firm has also predicted the EPS of PFE for FY 2022 at an EPS of $3.27.
The Quarterly Earnings for PFE
There have been several research analysts who have made the stocks of this company their subject. SVB Leerink has already increased the objective price on the shares of the company to $43- and has already given the stock a rating of ‘market outperform’. This was sent out through one of the research reports on the 28th of October. Zacks Investment Research has already upgraded the shares of the company from a rating of ‘hold’ to ‘sell’- along with a price objective of $37 in one of their research reports that were sent out on the 29th of October.
The PFE shares traded at $41.73 last Friday- where the company had a quick ratio of 1.16, a current ratio of 1.42, and a debt-to-equity ratio fixed at 0,78. The market cap for the firm has been set at $231.95 billion, with a PEG growth ratio of 3.10, and a PE ratio of 16.56. The simple moving average for the company over 50-days is $37.72, while that of 200-days is $36.71.
PFE had previously announced the results of their earnings on the 27th of October, where the EPS reported was $0.72. The revenue earned by the company was $12.13 billion, with a net margin of 28.80%.
